Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study
This article is for subscribers only.
Bristol-Myers Squibb Co. said its experimental hepatitis C compounds, protease inhibitor asunaprevir combined with its NS5A inhibitor daclatasvir, cured 77 percent of difficult-to-treat patients 24 weeks after treatment ended, according to a mid-stage study.
Difficult-to-treat patients included those who didn’t respond to prior therapy and patients who were medically ineligible or intolerant to previous treatment, the company said in a statement today.